Feb 28, 2022 · We modeled loss of function (LOF) in four common anti-PD-1 antibody-responsive syngeneic tumors, MC38, Hepa1-6, CT-26 and EMT-6, by systematical depleting a series of TIL lineages to explore...

To better understand how PD-1 blockade therapy modulates the tumor-host interactions, we evaluated three syngeneic murine tumor models, the BRAFV600E -driven YUMM1.1 and YUMM2.1 melanomas, and the carcinogen-induced murine colon adenocarcinoma MC38.

Feb 21, 2017 · CT26 and MC38 are two immunogenic 14, 15 colon tumour models that demonstrate PD-L1 expression on tumour cells as well as tumour infiltrating immune cells in vivo (Fig. 1c), with increased...

Curcumin restored DC functions in xenogeneic nude mouse model implanted with high IL-6-producing human clear cell ovarian cancer cells. The combination of curcumin and PD-1/PD-L1 Abs demonstrated a synergistic anti-tumor activity in MC38 murine tumor models.

Jan 2, 2018 · Analyses of wild-type and immunodeficient RAG1 knockout mice transplanted with MC38 cells reveal that upregulation of checkpoint molecules and infiltration by Tregs are the major tumor escape...

Oct 18, 2024 · To assess the synergy between SLIC–IFN-γ and PD-1 blockade in the setting of MC38 JAK1 KO and JAK2 KO, we treated established MC38 JAK1 KO and JAK2 KO tumors with one dose of PBS, SLIC control, and SLIC–IFN-γ, followed by repeated treatment with IgG control or αPD-1 mAb intraperitoneally.

6 days ago · PD-1: MC38 tumor model: Pre-clinical (Wang et al., 2019) mAb059c: PD-1: MC38 tumor model: Pre-clinical (Liu et al., 2019) Manipulating ubiquitination and deubiquitination signaling pathways presents promising strategies to enhance cancer immunotherapy (Liu et al., 2024a, Liu et al., 2022, Wu et al., 2023). Research has shown that modulating E3 ...

6 days ago · The antitumor activity of the combination was tested in vivo in (1) MC38, MB49, Pan02, and B16F10 syngeneic tumor models using acasunlimab and anti-PD-1 mouse-surrogate antibodies; and (2) triple knock-in mice expressing the human targets using an acasunlimab chimeric antibody (chi-acasunlimab) and pembrolizumab.

Mar 10, 2025 · (A) Experimental setting for the combination of ILDR and anti-PD-L1 Abs in MC38 colon cancer-bearing mice and timelines of sample harvesting. MC38 bearing C57BL/6J mice were subjected to intraperitoneal (i.p.) injections of isotype control Ab versus αPD-L1 Ab and abdominal ILDR (with increasing dosing of 0.25, 1, or 4 Gy).

Mar 5, 2025 · Interestingly, the results showed that the single treatment of anti-PD-1 (100 µg/mice) could result in a cure rate of~30% (3/10) in MC38 tumor-bearing mice, similarly to other reported before . while the combined treatment of MSC-EXO-miR-125b-5p and anti-PD-1 therapy resulted in~80% (8/10) mice reached complete regression, with tumor growth ...